Literature DB >> 20231183

Effect of neonatal jaundice and phototherapy on the frequency of first-year outpatient visits.

Danielle Usatin1, Petra Liljestrand, Michael W Kuzniewicz, Gabriel J Escobar, Thomas B Newman.   

Abstract

OBJECTIVE: The objective of this study was to determine whether either hyperbilirubinemia or inpatient phototherapy is associated with increased subsequent outpatient visit rates, a possible effect of the "vulnerable child syndrome."
METHODS: We compared 3 groups of otherwise well term and late-preterm infants who were born between 1995 and 2004 in Northern California Kaiser hospitals: group 1 never had a documented total serum bilirubin (TSB) level > or =12 mg/dL (n = 128 417); group 2 had a TSB level > or =17 and <23 mg/dL as outpatients between 48 hours and 7 days of age and did not receive inpatient phototherapy (n = 6777); and group 3 met criteria for group 2 but did receive inpatient phototherapy (n = 1765). We compared outpatient visit rates from 15 to 364 days of age adjusting for other predictors of visit rates by using Poisson and linear regression.
RESULTS: The mean total number of visits between 15 and 364 days was 9.83. Compared with group 1, adjusted total first-year visit rates were slightly increased in group 2 (adjusted incidence rate ratio: 1.04 [95% confidence interval: 1.02-1.05]) and group 3 (incidence rate ratio: 1.07 [95% confidence interval: 1.05-1.10]). The increases in visit rates were greatest for visits from 15 to 59 days of age, for specialty visits, and for unspecified diagnoses. These rates correspond to adjusted increases in total first-year visits (compared with group 1) of 0.36 visits in group 2 and 0.73 visits in group 3.
CONCLUSIONS: Neonatal jaundice and inpatient phototherapy are associated with only small increases in first-year outpatient visit rates, consistent with mild or infrequent contribution to the vulnerable child syndrome in this population.

Entities:  

Mesh:

Year:  2010        PMID: 20231183      PMCID: PMC3197860          DOI: 10.1542/peds.2009-0172

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  21 in total

1.  REACTIONS TO THE THREATENED LOSS OF A CHILD: A VULNERABLE CHILD SYNDROME. PEDIATRIC MANAGEMENT OF THE DYING CHILD, PART III.

Authors:  M GREEN; A J SOLNIT
Journal:  Pediatrics       Date:  1964-07       Impact factor: 7.124

2.  Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns.

Authors:  Thomas B Newman; Petra Liljestrand; Gabriel J Escobar
Journal:  Arch Pediatr Adolesc Med       Date:  2005-02

3.  Reactions to the threatened loss of a child: a vulnerable child syndrome, by Morris Green, MD, and Albert A. Solnit, MD, Pediatrics, 1964;34:58-66.

Authors:  C J Shonkoff
Journal:  Pediatrics       Date:  1998-07       Impact factor: 7.124

4.  Four-year follow-up of psychological reactions to false positive screening tests for congenital hypothyroidism.

Authors:  K Fyrö; G Bodegård
Journal:  Acta Paediatr Scand       Date:  1987-01

5.  Differences in health care utilization between parents who perceive their child as vulnerable versus overprotective parents.

Authors:  M Thomasgard; W P Metz
Journal:  Clin Pediatr (Phila)       Date:  1996-06       Impact factor: 1.168

6.  Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more.

Authors:  Thomas B Newman; Petra Liljestrand; Rita J Jeremy; Donna M Ferriero; Yvonne W Wu; Esther S Hudes; Gabriel J Escobar
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

7.  Practice parameter: management of hyperbilirubinemia in the healthy term newborn. American Academy of Pediatrics. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia.

Authors: 
Journal:  Pediatrics       Date:  1994-10       Impact factor: 7.124

8.  The child vulnerability scale: an instrument to measure parental perceptions of child vulnerability.

Authors:  B W Forsyth; S M Horwitz; J M Leventhal; J Burger; P J Leaf
Journal:  J Pediatr Psychol       Date:  1996-02

9.  Perceptions of vulnerability 3 1/2 years after problems of feeding and crying behavior in early infancy.

Authors:  B W Forsyth; P F Canny
Journal:  Pediatrics       Date:  1991-10       Impact factor: 7.124

10.  Jaundice, terminating breast-feeding, and the vulnerable child.

Authors:  K Kemper; B Forsyth; P McCarthy
Journal:  Pediatrics       Date:  1989-11       Impact factor: 7.124

View more
  6 in total

Review 1.  The side effects of phototherapy for neonatal jaundice: what do we know? What should we do?

Authors:  Tao Xiong; Yi Qu; Stephanie Cambier; Dezhi Mu
Journal:  Eur J Pediatr       Date:  2011-04-01       Impact factor: 3.183

2.  Extreme hyperbilirubinemia and rescue exchange transfusion in California from 2007 to 2012.

Authors:  V K Bhutani; N F Meng; Y Knauer; B H Danielsen; R J Wong; D K Stevenson; J B Gould
Journal:  J Perinatol       Date:  2016-07-21       Impact factor: 2.521

3.  Invited commentary: does neonatal hyperbilirubinemia cause asthma?

Authors:  Michael W Kuzniewicz; Andrea C Wickremasinghe; Thomas B Newman
Journal:  Am J Epidemiol       Date:  2013-10-31       Impact factor: 4.897

4.  Umbilical cord bilirubin as a predictor of neonatal jaundice: a retrospective cohort study.

Authors:  Kelsey D J Jones; S E Grossman; Dharshini Kumaranayakam; Arati Rao; Greg Fegan; Narendra Aladangady
Journal:  BMC Pediatr       Date:  2017-09-20       Impact factor: 2.125

5.  Ultrastructural Study of Rat Testis Following Conventional Phototherapy during Neonatal Period.

Authors:  Hare Krishna; Asha Changil; M Srinivas; Tara Sankar Roy; Tony George Jacob
Journal:  J Microsc Ultrastruct       Date:  2018 Oct-Dec

6.  Prevalence and burden of illness of treated hemolytic neonatal hyperbilirubinemia in a privately insured population in the United States.

Authors:  Tzy-Chyi Yu; Chi Nguyen; Nancy Ruiz; Siting Zhou; Xian Zhang; Elaine A Böing; Hiangkiat Tan
Journal:  BMC Pediatr       Date:  2019-02-11       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.